News Medical36m
Multigene RNA signature enhances treatment strategies for triple negative breast cancer
Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise as a way to improve disease-free survival, finds a clinical trial published ...
Gene signature to tailor chemotherapy shows promise for improving breast cancer survival
Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.
BioPharma Dive9h
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...
FiercePharma9h
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...
BioSpace11h
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...
The Pharma Letter12h
Sangamo shares jump as FDA clears faster gene therapy pathway
Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...
BioWorld17h
Japan mulls ways to boost cell, gene therapy approvals
The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in ...
Accelerated Approval Path Boosts Sangamo Biosciences’ Outlook: Buy Rating Reiterated
Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) and keeping the ...
Sangamo announces alignment with FDA on ST-920 accelerated approval pathway
Sangamo (SGMO) announced the outcome of a recent interaction with the FDA, providing a clear regulatory pathway to accelerated approval for ...
What's Going On With Sangamo Therapeutics Shares Tuesday?
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an ...